Nivolumab plus focused brain radiation for melanoma spread
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign informed consent
- You have melanoma that cannot be removed by surgery, and it has measurable brain metastases sized 5 to 40 mm
- Your melanoma treatment plan uses stereotactic radiosurgery/radiation (focused radiation), not whole-brain radiation
- Your brain metastases have not had radiation or cancer medicines before (certain past surgery is allowed)
- You don’t have brain symptoms at enrollment and you are not taking steroid medicines for brain symptoms
- You can have an MRI with contrast dye and your blood, liver, and kidney tests are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This Phase 2 trial studies a specific sequence of immune medicines for people with stage 3 or 4 melanoma that has spread or cannot be removed. It’s designed for melanoma that worsened after prior PD-1 treatment, aiming to shrink tumors and control disease.
This trial tests if combining targeted radiation (SBRT) with standard immunotherapy works better for melanoma that has spread to a few spots in the body (but not the brain). It is for people who have not yet had treatment for their current spread.
This trial tests a combination of a drug that stops blood vessel growth (bevacizumab), immunotherapy, and focused radiation to treat melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach shrinks tumors and improves outcomes.
This Phase 2 study tests whether nivolumab plus relatlimab can shrink or control melanoma that has spread to the brain. It may help by boosting the immune system to attack the cancer, including melanoma in brain areas that can’t be treated with prior focused radiation.
Hear when a new Melanoma Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.